PatientsHCP
This site is for US Health Care Professionals only

Discover more about ENTRESTO® 

Find educational resources to learn more about heart failure (HF) and ENTRESTO 

2022 AHA/ACC/HFSA HF Guideline Pocket Guide
2022 AHA/ACC/HFSA HF Guideline Pocket Guide
Download
Switch In-Office Brochure Thumbnail

ENTRESTO Initiation Guide for Providers

Download
Contact a Sales Specialist

If you're looking for more information about ENTRESTO, connect with one of our Sales Specialists. 

  • Clinical product information 

  • General access information 

  • Co-pay and adherence support options  

  • Sales Specialists do not have access to patient-level data 

Contact a Sales Specialist

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

Important Safety Information

BOXED WARNING: FETAL TOXICITY

  • When pregnancy is detected, discontinue ENTRESTO as soon as possible
  • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus

ENTRESTO is contraindicated in patients with hypersensitivity to any component...

Indication

ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal.

LVEF is a variable measure, so use clinical judgment in deciding whom to treat.

Click or scroll to see IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING AND INDICATION

Definitions
ACC, American College of Cardiology; AHA, American Heart Association; HFSA, Heart Failure Society of America.

Reference
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.